FDA Drug Information Updates-logo

FDA Drug Information Updates

ReachMD

FDA Drug Information Updates is a series featuring the U.S. Food and Drug Administration initiatives, programs, and other information that health care professionals can use to help their patients safely use FDA-regulated products. Listen to subject matter experts from the FDA discuss topical and urgent insights about approved drug products in this informative series.

FDA Drug Information Updates is a series featuring the U.S. Food and Drug Administration initiatives, programs, and other information that health care professionals can use to help their patients safely use FDA-regulated products. Listen to subject matter experts from the FDA discuss topical and urgent insights about approved drug products in this informative series.
More Information

Location:

United States

Networks:

ReachMD

Description:

FDA Drug Information Updates is a series featuring the U.S. Food and Drug Administration initiatives, programs, and other information that health care professionals can use to help their patients safely use FDA-regulated products. Listen to subject matter experts from the FDA discuss topical and urgent insights about approved drug products in this informative series.

Language:

English


Episodes

The FAERS Public Dashboard and its Value to the Pharmaceutical Industry

7/31/2018
More
The FDA has made strides in improving transparency and data access, and has implemented tools to allow the pharmaceutical industry and the public to transform raw data into usable information. One of these tools is called the FDA Adverse Event Reporting System (FAERS) Public Dashboard. In this episode, the architects of the FAERS Public Dashboard – Deputy Director of the Regulatory Science Staff Suranjan De, and Acting Team Lead in Regulatory Science Information Sanjay Sahoo—both of CDER’s...

Duration:00:24:44

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer

5/18/2017
More
FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Released May 18, 2017

Duration:00:05:59

Introducing FDA's Drug Information Soundcast in Clinical Oncology (DISCO)

5/16/2017
More
In the FDA's inaugural Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode, Dr. Richard Pazdur, director of the FDA Oncology Center of Excellence, talks with hosts Dr. Sanjeeve Bala and Dr. Abhilasha Nair about this new podcast series.

Duration:00:03:29

FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin

5/16/2017
More
Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, be added to the canagliflozin drug labels to describe this risk. Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the...

Duration:00:03:00

FDA Restricts Use of Prescription Codeine and Tramadol Pain Medicines in Children

4/20/2017
More
The Food and Drug Administration (FDA) is restricting the use of codeine and tramadol medicines in children. Codeine is approved to treat pain and cough, and tramadol is approved to treat pain. These medicines carry serious risks, including slowed or difficult breathing and death, which appear to be a greater risk in children younger than 12 years, and should not be used in these children. These medicines should also be limited in some older children. Single-ingredient codeine and all...

Duration:00:02:59

New Safe Use Requirements for Long-Acting Beta-Agonists (LABAs)

2/23/2010
More
FDA is recommending new safety measures to improve the safe use of long acting beta agonists (LABAs).

Duration:00:01:59

FDA: Product Confusion with Maalox Total Relief and Maalox Liquid Products

2/18/2010
More
The FDA has issued a public health advisory regarding serious medication errors that have arisen when consumers used Maalox Total Relief, the upset stomach reliever and anti-diarrheal medication,by mistake, when they had intended to use one of the traditional Maalox liquid antacid products.

Duration:00:02:59

FDA: Advisory on Body Building Products

6/17/2009
More
On July 28th, 2009, the FDA issued an advisory recommending that consumers do not use body building products marketed as containing steroids or steroid-like substances, due to potential serious health risks. Listen now for the full advisory.

Duration:00:02:51

FDA: Addressing Concerns About Marketing Unapproved Drugs

8/27/2008
More
Host: Charles Turck, PharmD Guest: Jason Woo, MD, MPH The Federal Food, Drug and Cosmetic Act generally requires drugs to be both safe and effective prior to marketing and widespread use.  But, despite this act, not all marketed drugs have undergone FDA approval. Dr. Jason Woo, associate director for Scientific and Medical Affairs in the Office of Compliance for the Center for Drug Evaluation and Research, discusses measures the FDA has undertaken to address the issue of these drugs...

Duration:00:12:59

FDA: Taking Action Against Marketing Unapproved Drugs

8/27/2008
More
Host: Charles Turck, PharmD Guest: Charles Lee, MD What specific action is the FDA undertaking to combat the marketing of unapproved drugs, and how can healthcare professionals play a role in tackling this public health issue? Dr. Charles Lee, a medical officer within the Division of New Drugs and Labeling Compliance at the Center for Drug Evaluation and Research, speaks with host Dr. Charles Turck about the FDA's top priorities in corralling products that pose key safety...

Duration:00:12:59